N eovascular age-related macular degeneration (AMD) is characterized by choroidal neovascularization (CNV), in which newly formed vessels from the underlying choroid grow beneath the retinal pigment epithelium (RPE) and the neuroretina. CNV may cause (sub) acute blindness because of bleeding or scar formation. 1 Although the morphology of angiogenesis in CNV secondary to AMD has been described in detail, the pathogenesis is still poorly understood.
Growth factors are acknowledged to play an important role in retinal neovascularizations. Vascular endothelial growth factor (VEGF), an endothelium-specific mitogen, is regarded as one of the most important ocular angiogenic factors, especially under hypoxic circumstances. 2, 3 Other angiogenic factors in ocular neovascularization include basic fibroblast growth factor, transforming growth factor-␤, platelet-derived growth factor, and insulin-like growth factor (IGF)-I. 2, 4 In an earlier study, we demonstrated that most CNVs in AMD express somatostatin receptor type 2A, which binds potential antiangiogenic somatostatin analogues. 5 Somatostatin receptors are present on cultured human retinal endothelial cells. Proliferation of retinal endothelial cells 6 and choroidal endothelial cells 7 can be inhibited by somatostatin analogues. In mice, inhibition of IGF-I by somatostatin analogues or by downregulation of growth hormone (GH) can decrease ischemia-induced retinal neovascularization. 8 IGF-I is a growthpromoting polypeptide that has mitogenic and differentiating effects on many cell types, among which are ocular vascular endothelial cells, 9 RPE cells, 10, 11 and neuronal cells. 12 IGF-I can act as a direct angiogenic factor on retinal endothelial cells, 6, 7 or indirectly through increased VEGF gene expression of cultured RPE cells. 13 Most studies describe the role of IGF-I in in vitro models 6,7,14 -17 or in situ in diabetic retinopathy. 18, 19 So far, IGF-I has not been studied in ARM.
The purpose of our study was to localize the expression of IGF-I and its receptor (IGF-IR) mRNA and IGF-IR protein in situ in normal human eyes and to examine the presence of expression in eyes with CNV, to elucidate its possible role in angiogenesis in AMD.
MATERIALS AND METHODS
The study was performed according to the tenets of the Declaration of Helsinki. Enucleation or surgical excision of subfoveal CNV was performed after obtaining the informed consent of the patient.
Patients
All eyes were retrieved from the Ophthalmic Pathology Department of the University Hospital of Rotterdam. Four enucleated eyes without ischemic disease (enucleated for other reasons) and three enucleated eyes with proliferative diabetic retinopathy (PDR) were used as the control. Fourteen eyes (five enucleated eyes, four donor eyes and five surgically removed subretinal neovascular membranes) of 13 patients with neovascular AMD were studied. The clinical and histologic diagnosis of the eyes and the classification of CNV are described in Table  1 . The eyes were processed for routine diagnostic procedures by fixation in 10% buffered formaldehyde and were embedded in paraffin. Five-micrometer sections were prepared for in situ hybridization and immunohistochemistry.
cDNA clone with a unique insert of human IGF-IR (IMAGE cDNA clone 150361, Research Genetics, Huntsville, AL). The insert was reduced to 270 bp by restriction with BamHI and AvaI and ligated in antisense and sense vectors (pBluescript SK and KS, respectively; Stratagene Europe, Amsterdam, The Netherlands). Escherichia coli X12Blue was transformed with these vectors, and proper colonies were isolated and grown. Sequence analysis was performed to verify the inserts. Digoxigenin-11-UTP labeled RNA probes were prepared according to the manufacturer's instructions (Roche Diagnostics, Mannheim, Germany), using T7 RNA polymerase.
In Situ Hybridization
Sections were deparaffinated with xylene and rehydrated. The slides were incubated in the following solutions: 0.2 N HCl, 0.3% Triton X-100 in phosphate-buffered saline (PBS), RNase-free proteinase K (5 L/mL for 20 minutes at 37°C) and 4% formalin in PBS. Subsequently, acetylation was performed with acetic anhydride in 0.1 M triethanolamine. The slides were rinsed in 2ϫ SSC (1ϫ SSC containing 150 mM NaCl and 15 mM sodium citrate) and preincubated in 50% formamide in 2ϫ SSC at 37°C. For hybridization, antisense and sense probes were diluted in hybridization solution (50% deionized formamide, 10% dextran sulfate, 4ϫ SSC [IGF-I] or 2ϫ SSC [IGF-IR], 1ϫ Denhardt's solution, 1 g/mL tRNA, and 250 g/mL herring sperm RNA) to a concentration of 400 ng/mL, and incubated at 68°C for 30 minutes. The hybridization solution was then layered onto the sections and hybridized overnight at 55°C in a humid chamber. Posthybridization washes were performed at 45°C for 30 minutes in the following solutions: 50% formamide in 2ϫ SSC, 50% formamide in 1ϫ SSC, 0.1ϫ SSC (IGF-IR), or 0.5ϫ SSC (IGF-I). The slides were incubated with RNase T1 (2 U/mL) in 2ϫ SSC and 1 mM EDTA in 37°C for 15 minutes and washed at 45°C with 1ϫ SSC and at room temperature with 2ϫ SSC. The digoxigenin-labeled hybrids were detected by antibody incubation performed according to the manufacturer's instructions (Roche Diagnostics) with the following modifications. A 1:1000 dilution of anti-digoxigenin (Fab) conjugated to alkaline phosphatase was used for a 2.5-hour incubation at room temperature or overnight at 4°C. Afterward, an extra washing step of 0.025% Tween in Tris-buffered saline (pH 7.5) was performed. For staining, sections were layered with detection buffer (0.1 M Tris-HCl, 0.1 M NaCl, 0.05 M MgCl 2 [pH 9.5]) containing 4-nitroblue tetrazolium chloride (NBT), 5-bromo-4-chloro-3-indolylphosphate (BCIP; both from Vector, Burlingame, CA) and 6% polyvinylalcohol (molecular weight 31,000 to 50,000, from Aldrich Chemical, Milwaukee, WI). The color reaction was performed in the dark and was stopped when the desired intensity of the resultant blue precipitate was reached. Sections were washed in 10 mM Tris-HCl and 1 mM EDTA (pH 8.0), counterstained with nuclear red solution, dehydrated with ethanol gradients, and mounted.
Immunohistochemistry
Polyclonal rabbit antibodies against IGF-IR (1:750 dilution) were obtained from Research Diagnostics (Flanders, NJ). Immunohistochemistry against IGF-I was not performed, because adequate antibodies for paraffin-embedded material are not available. Antibodies against pankeratin (monoclonal mouse antibodies; 1:100 dilution); factor VIII (monoclonal mouse antibodies; 1:50 dilution), and glial fibrillary acidic protein (GFAP; polyclonal rabbit antibodies; dilution 1:200) were obtained from Dako (Glostrup, Denmark). Monoclonal mouse antibodies against smooth muscle actin (SMA; 1:150 dilution) were obtained from Biogenex (San Ramon, CA). Sections were deparaffinated and rehydrated. Antigen retrieval was performed for the IGF-IR and pankeratin antibodies (microwave heating for 10 minutes) and for the factor VIII antibodies (pronase treatment for 20 minutes at 37°C). After the slides were blocked with normal goat serum (Dako, 1:10) for 15 minutes, 
Grading of Expression and Statistics
The slides were examined by light microscopy. Grading of mRNA and IGF-IR protein expression was performed in a masked fashion by two authors (ACL, CMM) twice and once, respectively. Slides were blinded and randomly graded per cell type in three categories (Table 2) : (1) no staining, (2) staining in less than 50% of cells, (3) staining in more than 50% of cells. Positive cell types in CNV were identified with pankeratin staining (RPE cells), factor VIII staining (vascular endothelial cells), GFAP staining (neuronal cells), and SMA (myofibroblasts) in consecutive slides, combined with cellular morphology at examination by light microscopy. Cells that did not meet these criteria were classified as other.
For inter-and intraobserver variability, a statistic was calculated.
RESULTS
In two eyes with neovascular AMD (Table 2 ; eyes CNV8 and CNV13) the normal retina, regarded as positive internal control, was negative with in situ hybridization. All mRNA appeared to be lost in these eyes.
In Situ Hybridization
IGF-I. In the normal retina, IGF-I mRNA expression (Figs. 1A, 1D) was found in the ganglion cell layer, inner nuclear layer, outer limiting membrane, RPE monolayer, and some cells in the choroid. Choriocapillary endothelial cells and retinal vessels were positive infrequently. Further expression was found in the lens epithelium, and in all corneal layers (not shown). Hybridization with the sense probe was negative. In eyes with CNV we found IGF mRNA in the retina in the same pattern as in normal retina. Staining in the preexistent RPE monolayer was similar to normal eyes. In 8 of 14 eyes with CNV, expression was found in vascular endothelial cells, some RPE cells, and fibroblast-like cells (Table 2 ; Figs. 2A, 2D, 2G, 2J). Eyes with PDR showed identical expression in retinal layers. In the preretinal membranes, endothelial cells from newly formed capillaries and fibroblast-like cells stained positive (Fig. 1G) . Hybridization with the sense probe was negative (Fig. 2L) .
IGF-I Receptor. In the normal eye mRNA of the IGF-IR (Figs. 1B, 1F ) was seen in the ganglion cell layer, inner and outer nuclear layer, and outer limiting membrane. The RPE was strongly positive. Endothelial cells of the choriocapillaris and the choroidal and intraretinal vessels were frequently positive. Further expression was found in the nonpigmented epithelium and to a lesser extent in the pigment epithelium of the ciliary body, the iris dilator muscle, the iris pigment epithelium, and iris endothelial cells. The lens epithelium and all corneal layers were also positive. Hybridization with the sense probe was negative. In all eyes with CNV, we found IGF-IR mRNA in endothelial cells of newly formed vessels, in RPE-cells and in the RPE monolayer, and in fibroblasts ( Table 2; Figs. 2B, 2E, 2H, 2K). Eyes with PDR showed expression in retinal layers and RPE similar to normal eyes. In the diabetic preretinal membranes (Fig. 1H ) endothelial cells from newly formed capillaries and fibroblast-like cells were positive. Hybridization with the sense probe was negative (Fig. 2M) .
Immunohistochemistry
In the normal eyes, we found IGF-IR protein in the choroidal vessels, in the RPE, and in all layers of the neuroretina (Figs. 1C,  1F) ; the choriocapillaris was negative. The negative controls showed no staining, except for the peptide control, in which staining of the RPE monolayer was not totally blocked compared with retinal staining, indicating an aspecific component in the RPE staining. In all eyes with CNV, we found the IGF-IR protein in RPE cells, and in 9 of 13 classifiable eyes, staining was present in newly formed vessels (Table 2; Figs. 2C, 2F, 2I). Eyes with PDR showed expression in the retina similar to that in normal eyes, and, in the diabetic preretinal membranes, endothelial cells from newly formed capillaries were positive (Fig. 1I) .
Statistics
Grading of mRNA and IGF-IR protein expression was performed in a masked fashion by two authors (ACL, CMM), twice, CNV1  0  0  0  1  2  2  2  2  1  1  1  1  CNV2  0  0  0  0  2  2  2  2  1  2  2  1  CNV3  1  2  1  1  2  1  1  2  1  1  0  0  CNV4  1  2  1  1  NC  NC  NC  NC  1  2  0  0  CNV5  1  1  0  1  1  2  1  1  1  2  NC  NC  CNV6  0  0  0  0  1  1  1  0  1  1  0  1  CNV7  NC  0  NC  1  1  2  1  1  0  1  0  0  CNV8  0  0  0  0  0  0  0  0  0  1  1  0  CNV9  2  2  1  1  2  2  2  2  NC  NC  NC  NC  CNV10  1 with an interval of 7 weeks, and once, respectively. For interobserver and intraobserver variabilities, was 0.75 and 0.83, respectively.
DISCUSSION
In the normal human retina, we found IGF-I and IGF-IR mRNA expression throughout the neuroretina in the same pattern, as described in other species. 21, 22 Expression in human RPE has not been described before in situ, but has been detected in cultured human RPE cells.
14 -16 IGF-I stimulates differentiation and proliferation of vascular endothelial cells, 23 RPE cells, 16 and neural retinal cells 12, 24 and is also neuroprotective. 24 -26 Our finding of protein and receptor colocalization confirms a paracrine-autocrine function of IGF-I in the normal human retina.
21,27
The observed hybridization signal of IGF-IR was much stronger than that of IGF-I. This may represent a real difference in expression, confirming the findings of higher IGF-IR expression in cultured human RPE. 14, 15 However, intensity of staining is not a reliable quantitative criterion, and the IGF-IR probe may be more sensitive than the IGF-I probe.
In CNV secondary to ARM, we demonstrated mRNA expression of IGF-I and IGF-IR in vascular endothelial cells, in RPE cells, and in fibroblast-like cells. Similarly, we found expression of IGF-I mRNA and its receptor in epiretinal membranes in eyes with PDR, including endothelial cells from newly formed capillaries and in fibroblast-like cells. This is in accordance with a previous diabetic retinopathy study, in which binding sites for IGF-I (receptors or binding proteins) were demonstrated in vessel walls, as well as in cells in fibrous tissue in human diabetic epiretinal membranes. 18 In human and rat diabetic retinas, IGF-I mRNA levels are decreased, 19, 28 but vitreous levels of IGF-I are elevated. 29 -33 Our findings confirm that intraocular synthesis may contribute to these elevated concentrations. 32 The pathogenesis of neovascular AMD involves the choroidal vasculature rather than the retinal vasculature, as in diabetic retinopathy. In vitro, IGF-I stimulates the proliferation of choroidal endothelial cells. 7 Therefore, synthesis of IGF-IR and IGF-I in endothelial and RPE cells in CNV may point toward a role for this growth factor in the pathogenesis of neovascular AMD, because both cell types appear to have an important role in this process. 1 IGF-I participates in ocular neovascularization. 23 It is involved in the degradation of basement membranes, and proteolysis of extracellular matrix, and in migration and proliferation of vascular endothelial cells. 6 Intravitreous injection of IGF-I produces preretinal neovascularization in rabbits 34 or microangiopathy resembling diabetic microangiopathy in pigs. 35 IGF-I also increases RPE cell migration and proliferation in vitro. 11 Furthermore, IGF-I induces upregulation of VEGF mRNA expression in RPE cells 13 and fibroblasts, 36 which in turn also stimulates endothelial cells. 13 Antagonism of IGF-IR suppresses retinal neovascularization and reduces the retinal endothelial cell response to VEGF, 37 which allows for the hypothesis that IGF-I has a permissive role in VEGF-induced neovascularization.
Inhibition of IGF-I, achieved with somatostatin analogues, 8 may occur at different levels. First, somatostatin inhibits the GH-IGF axis. Furthermore, somatostatin can inactivate the mitogenic potential of IGF-I directly by inactivating the phosphorylated, active form of IGF-IR. 23, 38 Finally, somatostatin can act directly as an antiangiogenic agent through binding to somatostatin receptors. 6 Therefore, somatostatin analogues may be an effective therapy for neovascular AMD. IGF-I is recruited in normal wound repair. 39, 40 This may partly explain the presence of IGF-I in CNV, because formation of the disciform lesion is regarded as normal wound repair. 1 In conclusion, in this descriptive study we localized the expression of IGF-I mRNA and IGF-IR protein and mRNA in the normal eye. The colocalization of protein and receptor indicates an autocrine function of IGF-I in the human retina. Furthermore, we detected synthesis of both IGF-I and its receptor, and IGF-IR protein in ocular neovascular membranes of patients with AMD and patients with diabetes. Because IGF-I participates in ocular neovascularization, synthesis of IGF-IR and IGF-I in vascular endothelial, RPE, and fibroblast-like cells in CNV may indicate a role for this growth factor in the pathogenesis of neovascular AMD. The exact role of the IGF family in CNV and its possible therapeutic possibilities are yet to be established.
